Loading clinical trials...
Loading clinical trials...
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
Conditions
Interventions
ATIR101
Cyclophosphamide
+2 more
Locations
42
United States
City of Hope National Medical Center
Duarte, California, United States
Moores UC San Diego Cancer Center
La Jolla, California, United States
UCLA Center for Health Sciences
Los Angeles, California, United States
Stanford University School of Medicine
Stanford, California, United States
Emory University
Atlanta, Georgia, United States
University of Kansas Cancer Center
Westwood, Kansas, United States
Start Date
November 29, 2017
Primary Completion Date
November 9, 2021
Completion Date
December 17, 2021
Last Updated
May 24, 2022
NCT06735690
NCT05564390
NCT06303193
NCT03050268
NCT06074666
NCT06847867
Lead Sponsor
Kiadis Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions